loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Fexuprazan

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Fexuprazan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Daewoong Regaining Rights to Fexuprazan in the USA and Canada
    Daewoong Regaining Rights to Fexuprazan in the USA and Canada

    05 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/daewoong-pharmaceutical-regaining-rights-to-fexuprazan-in-the-united-states-and-canada-upon-termination-of-license-agreement-with-neurogastrx-301841938.html

    PR NEWSWIRE
    05 Jun 2023
    Share Share
    Daewoong applies for approving its GE reflux drug in 4 Latin American countries
    Daewoong applies for approving its GE reflux drug in 4 Latin American countries

    23 May 2022

    // Lee Han-soo KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=13739

    Lee Han-soo KOREABIOMED
    23 May 2022
    Share Share
    Neurogastrx Agreement with Daewoong Pharmaceutical to Develop Fexuprazan
    Neurogastrx Agreement with Daewoong Pharmaceutical to Develop Fexuprazan

    08 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurogastrx-announces-agreement-with-daewoong-pharmaceutical-to-develop-fexuprazan-for-treatment-of-acid-related-gi-disorders-in-the-us-301308153.html

    PRNEWSWIRE
    08 Jun 2021
    Share Share